Yoshikazu Sukenaga Selected Research

NK30424A

3/2002

Oxidative modification of NK30424A and B enhance inhibitory effect on lipopolysaccharide-induced tumour necrosis factor-alpha promoter activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshikazu Sukenaga Research Topics

Disease

2	Myocardial Infarction 11/2003 - 11/2002
2	Hyperplasia 02/2003 - 11/2002
1	Body Weight (Weight, Body) 10/2015
1	Alopecia (Baldness) 04/2006
1	Osteosarcoma (Osteogenic Sarcoma) 04/2006
1	Fibrosis (Cirrhosis) 11/2002
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2002
1	Interstitial Cystitis (Interstitial Cystitis, Chronic) 11/2002
1	Necrosis 03/2002

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 10/2015 - 11/2002
3	Chymases (Chymase)IBA 11/2003 - 11/2002
2	acetamideIBA 02/2003 - 11/2002
2	NK3201IBA 02/2003 - 11/2002
1	Human Serum Albumin FDA LinkGeneric 10/2015
1	lysocellinIBA 04/2006
1	alopestatinIBA 04/2006
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2006
1	Etoposide (VP 16)FDA LinkGeneric 04/2006
1	Angiotensin IIIBA 11/2002
1	Bleomycin (Blenoxane)FDA LinkGeneric 11/2002
1	NK30424AIBA 03/2002
1	LipopolysaccharidesIBA 03/2002

Therapy/Procedure

1	Catheters 02/2003